On way to #ACR23 via Denver. good news - got upgraded, bad news late flight so tight connection. Looking forward to science, meeting in person and perfect weather….and did I say shopping, zoo, parks and food! @rheumnow https://t.co/611Y2QnfjR

What’s not to love 💗 about #San Diego #ACR23 convention center? @ACRheum Follow reports @RheumNow for great updates! https://t.co/6CrQ4ifnzt

@maferradastrong is an inspiration. She was driven to improve outcomes for relapsing polychondritis, the disease she lives with, & now she leads her field. Truly the model of a patient-physician, always so much to learn from her. #ACR23 Review Course @RheumNow @Polychondritis https://t.co/1HJSFqgWEK

Relapsing polychondritis RP is a systemic condition and not just inflammation in the ears 👂 Ferrara M #ACR23 @RheumNow https://t.co/BXvyWYMYa0

Outcome scores for TTP, using the PLASMIC score to decide on treatment for TTP, Ortel T, #ACR23 @RheumNow https://t.co/Gbn7ZqkH5Y

The role of caplacizumab in the treatment of TTP, Ortel T #ACR23 @RheumNow https://t.co/VAWOlNBRuh

Subchondral bone lesions in #OA on the weight bearing regions are the source of pain - David Walsh excellent talk summarizing pain mechanisms. #ACR23 @RheumNow

Recombinant ADAMTS13 therapy just @US_FDA approved - will save these patients recurrent plasma infusions (every couple of weeks for months), a big win. https://t.co/lKdWTMp2oc #ACR23 Review Course @RheumNow https://t.co/2NMbJvseiA

Summary of recommendations for thrombotic microangiopathy (TMA), think of ADAMTS13, Ortel T, #ACR23 @RheumNow https://t.co/eSaocPSLUH

RheumNow’s expanded coverage of the #ACR23 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.

Bummed to miss sunny San Diego but still excited to join #ACR23 @RheumNow Time to get some learnin' on! Informative review on the role of systemic treatments and the rheumatologists role in ocular inflammation. https://t.co/0nFDEZHfGW

Things for me to take back to the clinic in looking after JIA patients, Sadun R, #ACR23 @RheumNow https://t.co/YkiP4GZG19

Did you know about Tubulointerstitial nephritis uveitis (TINU) syndrome? Usually younger pts; uveitis may not be concurrent with the TIN. Risks: NSAID/abx, infx, genetics. Nice systematic review of this entity (link below). #boardquestion @rheumnow #ACR23 https://t.co/HDqLDHyGM6

Systemic inflammatory conditions related to scleritis #ACR23 @RheumNow https://t.co/qc6szUnOUl

Conditions diagnosed by ophthalmologists that require systemic therapy #ACR23 @RheumNow https://t.co/tPkdoH3m9c